688098 申联生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-2.3572.1114.1077.6659.670
总资产报酬率 ROA (%)-2.1901.9703.8157.0808.745
投入资产回报率 ROIC (%)-2.3342.0984.0797.6039.287

边际利润分析
销售毛利率 (%)58.39870.83375.22975.73183.687
营业利润率 (%)-29.18311.98022.89635.90343.642
息税前利润/营业总收入 (%)-29.69611.72122.39834.70443.748
净利润/营业总收入 (%)-28.8319.90118.55629.14438.305

收益指标分析
经营活动净收益/利润总额(%)98.05285.004103.27990.13884.436
价值变动净收益/利润总额(%)-3.02315.9604.4429.59010.216
营业外收支净额/利润总额(%)0.7290.403-0.917-2.1481.733

偿债能力分析
流动比率 (X)6.4487.8207.2576.4617.498
速动比率 (X)5.1576.3596.0715.5506.826
资产负债率 (%)6.4815.4536.7427.8507.805
带息债务/全部投入资本 (%)0.567-0.1680.018-0.191--
股东权益/带息债务 (%)17,371.017-59,367.630540,213.360-51,981.35666,608.363
股东权益/负债合计 (%)1,426.8231,712.6371,383.2681,178.6061,181.363
利息保障倍数 (X)99.294-38.060-77.237-78.109-65.901

营运能力分析
应收账款周转天数 (天)389.033296.208204.417141.7820.000
存货周转天数 (天)386.865464.908483.748361.2810.000